Lymph Node CancerNCT07538960
Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica.
An observational study of Lymph Node Cancer and Cutaneous, run by Caja Costarricense de Seguro Social at 1 site in Costa Rica.
Trial summary
Adult patients (≥18 years) with confirmed cutaneous T-cell lymphoma evaluated at Hospital México between 2019 and 2025 will be retrospectively analyzed using EDUS records to describe their epidemiological profile, clinical characteristics, treatments, and outcomes. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lymph Node Cancer, Cutaneous, T-cell Lymphoma
- How many people
- 350 participants
- Where
- 1 siteCosta Rica
- Study dates
- May 2026to May 2027
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: he study population will consist of adult patients (≥18 years) of both sexes with a confirmed diagnosis of cutaneous T-cell lymphoma, established through clinical, histopathological, and immunohistochemical criteria, and documented in EDUS at the Dermatology Service of Hospital México between January 2019 and December 2025. Patients must have at least one recorded dermatological evaluation during the study period and must have received some form of treatment, including skin-directed therapies (phototherapy, topical treatments, localized radiotherapy) and/or systemic therapies. Patients with insufficient or incomplete clinical records that prevent adequate diagnostic classification, staging, therapeutic characterization, or evaluation of clinical evolution will be excluded, as well as those with a presumptive diagnosis without histopathological confirmation, duplicate or inconsistent records, patients attended outside the study period, those outside the defined age range, and patients.
Who may be able to join
- Patients with a confirmed diagnosis of cutaneous T-cell lymphoma, established through clinical, histopathological, and immunohistochemical criteria, documented in EDUS of Hospital México in the Dermatology Service of Hospital México during the period between January 2019 and December 2025.
- Patients aged 18 years or older, of both sexes.
- Patients with at least one dermatological evaluation recorded during the study period.
- Patients who, having a confirmed diagnosis, have received some modality of treatment, including skin-directed therapies (phototherapy, topical treatments, localized radiotherapy) and/or systemic treatments.
Who cannot join
- Clinical records that are insufficient or incomplete, preventing adequate diagnostic classification, staging, therapeutic characterization, or evaluation of clinical evolution.
- Patients with a presumptive diagnosis of cutaneous T-cell lymphoma without histopathological confirmation.
- Duplicate or inconsistent records that hinder the correct identification and classification of the patient.
- Patients attended outside the established study period.
- Patients outside the age range.
- Patients who do not belong to the Dermatology Service of Hospital México.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Costa Rica1 site
Hospital México
San José, Uruca, 10107
Daniel Barquero-Orias, Dermatologist, +506 83411026, debarque@ccss.sa.cr
Raquel Ramirez-Fallas, Dermatology Resident
About this study
Official title: Epidemiological Profile and Therapeutic Management of Patients Diagnosed With Cutaneous T-cell Lymphoma Evaluated in the Dermatology Department of Hospital México During the Period From 2019 to 2025.
Adult patients (≥18 years) with confirmed cutaneous T-cell lymphoma evaluated at Hospital México between 2019 and 2025 will be retrospectively analyzed using EDUS records to describe their epidemiological profile, clinical characteristics, treatments, and outcomes.
Read the detailed description
This retrospective observational study will analyze adult patients (≥18 years) with a confirmed diagnosis of cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México between January 2019 and December 2025. Data will be obtained from electronic medical records (EDUS), including sociodemographic characteristics, clinical presentation, histopathological and immunohistochemical findings, disease staging, treatment modalities, and clinical outcomes.
Patients must have at least one documented dermatological evaluation and have received treatment, including skin-directed therapies and/or systemic therapies. Records that are incomplete, inconsistent, or lack histopathological confirmation will be excluded.
The study aims to characterize local epidemiological and therapeutic patterns and describe clinical outcomes using descriptive statistical analysis, providing updated real-world evidence to support clinical decision-making and optimize management strategies for cutaneous T-cell lymphoma in a national referral center.
- Conditions
- Lymph Node Cancer, Cutaneous, T-cell Lymphoma
- Keywords
- Linfoma, Cutaneous Lymphoma, T-Cell Lymphoma, Therapy
- Medical subject headings
- Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous
What is being measured
The primary outcome is the main question the study is designed to answer.
Characterize the epidemiology
Characterize the epidemiology of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México.
Measured: 2019-2025
Characterize the therapeutic management
Characterize the therapeutic management of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México
Measured: 2019-2025.
Secondary outcomes (7)
Describe the sociodemographic/epidemiological characteristics
To describe the sociodemographic and epidemiological characteristics of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México during the period from 2019 to 2025.
Measured: 2019-2025
Classify the clinical manifestations/clinical subtypes
Classify the clinical manifestations and clinical subtypes of cutaneous T-cell lymphoma present in the studied population.
Measured: 2019-2025
Identify the histopathological/ immunohistochemical findings
To identify the histopathological and immunohistochemical findings associated with cutaneous T-cell lymphoma in the included patients.
Measured: 2019-2025
Analyze the therapeutic management modalities.
Analyze the therapeutic management modalities used, including skin-directed therapies and their outcomes.
Measured: 2019-2025
identify the clinical stage at the time of diagnosis
identify the clinical stage of the disease at the time of diagnosis according to the TNMB staging system.
Measured: 2019-2025
Evaluation of imaging studies and laboratory.
Evaluate imaging studies and laboratory findings of patients with cutaneous T-cell lymphoma during the follow-up period.
Measured: 2019-2025
Evaluation of clinical course and outcomes.
Evaluation of clinical course and outcomes of patients with cutaneous T-cell lymphoma during the follow-up period.
Measured: 2019-2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Apr 2026
- Study startMay 2026 (estimated)
- Primary completionMay 2027 (estimated)
- Study completionMay 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lymph Node CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 350 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Caja Costarricense de Seguro Social
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Daniel Barquero Orias, Caja Costarricense de Seguro Social
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07538960
- Sponsor's protocol ID
- CEC HM 002-2026
- Status last verified
- Apr 2026
- First submitted
- 11 Apr 2026
- Last updated
- 20 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: According to protocol